Shotgun and targeted proteomics reveal that pre-surgery serum levels of LRG1, SAA, and C4BP may refine prognosis of resected squamous cell lung cancer

Journal of Molecular Cell Biology

Volumn 4, Issue 5, 2012, Pages 344-347

  Liu, Yan Sheng ^a   Luo, Xiao Yang ^b,c   Li, Qing Run ^a   Li, Hong ^a   Li, Chen ^a   Ni, Hong ^a   Li, Rong Xia ^a   Wang, Rui ^b,c   Hu, Hai Chuan ^b,c   Pan, Yun Jian ^b,c   Chen, Hai Quan ^b,c   Zeng, Rong ^a  

^a Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C4B BINDING PROTEIN; COMPLEMENT COMPONENT C4B BINDING PROTEIN ALPHA; PROTEIN; PROTEIN LRG1; SERUM AMYLOID A; UNCLASSIFIED DRUG;

ADULT; AGED; CANCER SURGERY; FEMALE; HUMAN; LETTER; LUNG RESECTION; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PROGNOSIS; PROTEIN DETERMINATION; PROTEOMICS;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; COMPLEMENT C4B-BINDING PROTEIN; FEMALE; GLYCOPROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROTEOMICS; SERUM AMYLOID A PROTEIN;

EID: 84867421373     PISSN: 16742788     EISSN: 17594685     Source Type: Journal    
DOI: 10.1093/jmcb/mjs050     Document Type: Letter

References (13)

1. Chen, H.Y., Yu, S.L., Chen, C.H., et al. (2007). A fivegene signature and clinical outcome in non-smallcell lung cancer. N. Engl. J. Med. 356, 11-20.
2. Cho,W.C., Yip, T.T.,Cheng,W.W., et al. (2010). Serum amyloid A is elevated in the serum of lung cancer patients with poor prognosis. Br. J. Cancer 102, 1731-1735.
3. Guo, N.L., Wan, Y.W., Tosun, K., et al. (2008). Confirmation of gene expression-based prediction of survival in non-small cell lung cancer. Clin. Cancer Res. 14, 8213-8220.
4. Herbst, R.S., Heymach, J.V., and Lippman, S.M. (2008). Lung cancer. N. Engl. J. Med. 359, 1367-1380.
5. Hu, Z., Chen, X., Zhao, Y., et al. (2010). Serum microRNA signatures identified in a genomewide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J. Clin. Oncol. 28, 1721-1726.
6. Huttenhain, R., Malmstrom, J., Picotti, P., et al. (2009). Perspectives of targeted mass spectrometry for protein biomarker verification. Curr. Opin. Chem. Biol. 13, 518-525.
7. Jeong, Y., Xie, Y., Xiao, G., et al. (2010). Nuclear receptor expression defines a set of prognostic biomarkers for lung cancer. PLoS Med. 7, e1000378.
8. Kadara, H., Behrens, C., Yuan, P., et al. (2011). A five-gene and corresponding-protein signature for stage-I lung adenocarcinoma prognosis. Clin. Cancer Res. 17, 1490-1501.
9. Li, R.X., Chen, H.B., Tu, K., et al. (2008). Localized-statistical quantification of human serum proteome associated with type 2 diabetes. PLoS One 3, e3224.
10. Luo, X., Liu, Y., Wang, R., et al. (2011). A highquality secretome of A549 cells aided the discovery of C4b-binding protein as a novel serum biomarker for non-small cell lung cancer. J. Proteomics 74, 528-538.
11. Potti, A., Mukherjee, S., Petersen, R., et al. (2006). A genomic strategy to refine prognosis in earlystage non-small-cell lung cancer. N. Engl. J. Med. 355, 570-580.
12. Shedden, K., Taylor, J.M., Enkemann, S.A., et al. (2008). Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat. Med. 14, 822-827.
13. Tomida, S., Takeuchi, T., Shimada, Y., et al. (2009). Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. J. Clin. Oncol. 27, 2793-2799.